| Literature DB >> 32862457 |
Chang-Sheng Zhan1,2,3, Jia Chen1,2, Jing Chen1,2, Li-Gang Zhang1,2, Yi Liu1,2,3, He-Xi Du1,2, Hui Wang1,2, Mei-Juan Zheng4, Zi-Qiang Yu5, Xian-Guo Chen1,2,3, Li Zhang1,2,3, Chao-Zhao Liang1,2,3.
Abstract
Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) is a complicated syndrome characterized by genitourinary pain in the absence of bacterial infection. Th17 cell-driven autoimmunity has been proposed as a cause of CP/CPPS. However, the factors that promote Th17-driven autoimmunity in experimental autoimmune prostatitis (EAP) and the molecular mechanisms are still largely unknown. Here, we showed that Th17 cells were excessively activated, and blockade of IL-17A could effectively ameliorate various symptoms in EAP. Furthermore, we revealed that calcium/calmodulin-dependent kinase Ⅳ (CaMK4), especially Thr196 p-CaMK4 was increased in the Th17 cells of the EAP group, which were activated by intracellular cytosolic Ca2+ . Pharmacologic and genetic inhibition of CaMK4 decreased the proportion of Th17 cells, and the protein and mRNA level of IL-17A, IL-22, and RORγt. The phosphorylation of CaMK4 was dependent on the increase in intracellular cytosolic Ca2+ concentration in Th17 cells. A mechanistic study demonstrated that inhibition of CaMK4 reduced IL-17A production by decreasing the phosphorylation of Akt-mTOR, which was well accepted to positively regulate Th17 differentiation. Collectively, our results demonstrated that Ca2+ -CaMK4-Akt/mTOR-IL-17A axis inhibition may serve as a promising therapeutic strategy for CP/CPPS.Entities:
Keywords: Akt/mTOR signaling; CaMK4; EAP; Th17
Year: 2020 PMID: 32862457 DOI: 10.1096/fj.201902910RRR
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191